Incidence and Impact of COVID-19 in MS
A Survey From a Barcelona MS Unit
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 22, 2020
- Accepted in final form November 20, 2020
- First Published January 27, 2021.
Author Disclosures
- Maria Sepúlveda, MD* (msepulve{at}clinic.cat),
- Sara Llufriu, MD, PhD* (sllufriu{at}clinic.cat),
- Eugenia Martínez-Hernández, MD, PhD (emmartinez{at}clinic.cat),
- Martí Català, MSc (marticatalasabate{at}gmail.com),
- Montse Artola, RN (martola{at}clinic.cat),
- Ana Hernando, RN (ahernand{at}clinic.cat),
- Carmen Montejo, MD (montejo{at}clinic.cat),
- Irene Pulido-Valdeolivas, MD, PhD (irenepulidovaldeolivas{at}gmail.com),
- Eloy Martínez-Heras, PhD (emartind{at}clinic.cat),
- Mar Guasp, MD (guasp{at}clinic.cat),
- Elisabeth Solana, PhD (elisabeth.solana{at}idibaps.org),
- Laura Llansó, MD (llanso{at}clinic.cat),
- Domingo Escudero, MD, PhD (descudero{at}clinic.cat),
- Marta Aldea, MD, MPH (maldea{at}clinic.cat),
- Clara Prats, PhD (clara.prats{at}upc.edu),
- Francesc Graus, MD, PhD (francesc.graus{at}idibaps.org),
- Yolanda Blanco, MD, PhD† (yblanco{at}clinic.cat) and
- Albert Saiz, MD, PhD†
- Maria Sepúlveda, MD* (msepulve{at}clinic.cat),
- Sara Llufriu, MD, PhD* (sllufriu{at}clinic.cat),
NONE
NONE
I have received speaking honoraria from Biogen Idec, Novartis, Teva, Genzyme and Merck.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I receive research support from the Spanish Government (PI15/00587).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eugenia Martínez-Hernández, MD, PhD (emmartinez{at}clinic.cat),
- Martí Català, MSc (marticatalasabate{at}gmail.com),
- Montse Artola, RN (martola{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana Hernando, RN (ahernand{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Carmen Montejo, MD (montejo{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Irene Pulido-Valdeolivas, MD, PhD (irenepulidovaldeolivas{at}gmail.com),
NONE
NONE
(1) Roche Spain, travel funding. (2) Novartis, travel funding. (3) Genzyme, travel funding.
NONE
(1)affordable eye tracking system to measure eye movements in neurological diseases.
NONE
1)UCB pharma, MSL, 6 months
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Aura innovative robotics
NONE
NONE
(1) Aura innovative robotics,1 year Stock/Stock Options, Medical Equipment & Materials: (1) Aura innovative robotics,1 year
NONE
NONE
- Eloy Martínez-Heras, PhD (emartind{at}clinic.cat),
- Mar Guasp, MD (guasp{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elisabeth Solana, PhD (elisabeth.solana{at}idibaps.org),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Llansó, MD (llanso{at}clinic.cat),
- Domingo Escudero, MD, PhD (descudero{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marta Aldea, MD, MPH (maldea{at}clinic.cat),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Clara Prats, PhD (clara.prats{at}upc.edu),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Ministerio de Ciencia, Innovación y Universidades and FEDER, with the project PGC2018-095456-B-I00
NONE
La Caixa Foundation (ID 100010434), under agreement LCF/PR/GN17/50300003
NONE
NONE
NONE
NONE
NONE
NONE
- Francesc Graus, MD, PhD (francesc.graus{at}idibaps.org),
NONE
NONE
NONE
Associated Editor for MedLink Neurology
I hold a patent for the use of IgLON5 antibodies as diagnostic test
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I receive royalties from Euroimmun for the use of IgLON5 as an autoantibody test
NONE
NONE
NONE
- Yolanda Blanco, MD, PhD† (yblanco{at}clinic.cat) and
NONE
NONE
Dr.Blanco received speaking honoraria from Biogen, Novartis and Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD, PhD†
NONE
NONE
compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, Alexion,and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.
- Correspondence
Dr. Saiz asaiz{at}clinic.cat
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.